Kevin H Mayo Selected Research

Angiogenesis Inhibitors

1/2021	Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
6/2012	Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
5/2011	Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.
7/2008	Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.
2/2007	Early in vivo assessment of angiostatic therapy efficacy by molecular MRI.
2/2007	Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.
10/2006	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.
4/2006	Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
8/2005	Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein.
6/2005	Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin H Mayo Research Topics

Disease

40	Neoplasms (Cancer) 01/2021 - 12/2002
4	Inflammation (Inflammations) 12/2021 - 01/2009
4	Communicable Diseases (Infectious Diseases) 06/2013 - 05/2007
3	Pre-Eclampsia (Preeclampsia) 01/2021 - 12/2018
3	Atherosclerosis 01/2017 - 01/2009
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2020
2	Cognitive Dysfunction 01/2021 - 01/2020
1	Thrombosis (Thrombus) 01/2022
1	Pathologic Processes 01/2021
1	Neuroblastoma 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 11/2019
1	Fibrosarcoma 01/2019
1	Leukemia 03/2018
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2018
1	Acute Lung Injury 01/2017
1	Carcinoma (Carcinomatosis) 01/2015
1	Bacteremia 06/2013
1	Melanoma (Melanoma, Malignant) 03/2012
1	Hypoxia (Hypoxemia) 06/2007
1	Neoplasm Metastasis (Metastasis) 02/2007
1	Septic Shock (Toxic Shock Syndrome) 12/2006
1	Endotoxemia 12/2006

Drug/Important Bio-Agent (IBA)

15	Peptides (Polypeptides)IBA 01/2022 - 11/2003
13	Angiogenesis InhibitorsIBA 01/2021 - 01/2003
10	Galectin 1 (LGALS1)IBA 01/2021 - 10/2006
6	Proteins (Proteins, Gene)FDA Link 12/2021 - 08/2005
5	ChemokinesIBA 12/2021 - 01/2009
5	Pharmaceutical PreparationsIBA 10/2013 - 07/2006
4	Galectins (Galectin)IBA 12/2021 - 03/2018
4	AngiostatinsIBA 09/2009 - 01/2003
4	EndostatinsIBA 09/2009 - 03/2005
3	Polysaccharides (Glycans)IBA 12/2021 - 07/2009
3	calix(4)areneIBA 01/2021 - 06/2012
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 11/2006
3	Oxygen (Dioxygen)IBA 11/2015 - 02/2007
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2020
2	LectinsIBA 01/2021 - 01/2020
2	Conjugate VaccinesIBA 07/2019 - 01/2018
2	VaccinesIBA 07/2019 - 01/2018
2	Calixarenes (Calixarene)IBA 01/2015 - 10/2013
2	Cytotoxins (Cytolysins)IBA 10/2013 - 01/2010
2	compound 0118IBA 06/2012 - 07/2008
2	Liposomes (Liposome)IBA 03/2012 - 02/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2009 - 06/2007
2	LigandsIBA 05/2007 - 02/2007
1	peptide IIBA 01/2022
1	Emodin (Archin)IBA 01/2021
1	Galectin 3 (LGALS3)IBA 01/2021
1	Lactose FDA LinkGeneric 01/2020
1	Androgen Receptors (Androgen Receptor)IBA 11/2019
1	raf KinasesIBA 01/2019
1	Biological ProductsIBA 03/2018
1	Fibronectins (Fibronectin)IBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2013
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 06/2013
1	Cell Surface ReceptorsIBA 03/2013
1	Contrast MediaIBA 03/2012
1	GlycoconjugatesIBA 04/2010
1	acylfulveneIBA 01/2010
1	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2010
1	NF-kappa B (NF-kB)IBA 09/2009
1	ProlactinIBA 09/2009
1	Transcription Factors (Transcription Factor)IBA 09/2009
1	Galactose (Galactopyranose)FDA LinkGeneric 07/2009
1	MannansIBA 07/2009
1	galactomannanIBA 07/2009
1	Met- RANTESIBA 01/2009
1	Chemokine CCL5IBA 01/2009
1	irofulvenIBA 07/2008
1	Bevacizumab (Avastin)FDA Link 06/2007
1	PeptidomimeticsIBA 05/2007
1	Therapeutic UsesIBA 05/2007
1	KisspeptinsIBA 02/2007
1	LipopolysaccharidesIBA 12/2006
1	EndotoxinsIBA 12/2006
1	CytokinesIBA 12/2006
1	Decitabine FDA Link 11/2006
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 11/2006
1	Histone Deacetylase InhibitorsIBA 11/2006
1	trichostatin A (A 300)IBA 11/2006
1	Cell Adhesion MoleculesIBA 11/2006
1	Histones (Histone)IBA 11/2006
1	DNA (Deoxyribonucleic Acid)IBA 11/2006
1	pyrimidin-2-one beta-ribofuranosideIBA 11/2006
1	Recombinant ProteinsIBA 10/2006
1	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 10/2006
1	VimentinIBA 10/2006
1	Membrane Proteins (Integral Membrane Proteins)IBA 07/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 04/2006
1	A 17 (A-17)IBA 03/2005
1	Amino Acids FDA Link 03/2005
1	Opioid Analgesics (Opioids)IBA 03/2005
1	NociceptinIBA 03/2005

Therapy/Procedure

12	Therapeutics 11/2015 - 04/2006
3	Radiotherapy 01/2011 - 06/2005
2	Immunotherapy 05/2011 - 04/2006
2	Injections 06/2005 - 05/2003
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2020
1	Castration 11/2019
1	Subcutaneous Injections 10/2006